Notably, when comparing the EV profile of MS patients and HC, a few markers revealed significant differences: Galactosylceramide (GALC), a myelin-specific lipid, was increased in CD63+EVs of MS patients; CD68 (LAMP4), which is specific for monocytes, macrophages, and microglia, was increased in CD81+EVs of MS patients; and CD29 (integrin beta 1) was decreased in CD81+EVs of MS patients. The gene discussed is CD68; the disease is myeloid sarcoma.